News | March 25, 2013

Gamma Medica’s LumaGEM Breast Imaging Business Acquired by Psilos Group

Will continue and expand molecular breast imaging operation

LumaGEM Molecular Breast Imaging Gamma Medica Inc. Psilos Group Managers

March 25, 2013 — The LumaGEM Molecular Breast Imaging (MBI) business of Gamma Medica Inc. has been acquired through a chapter 11 sale by Imaging Acquisition Inc., an entity controlled by healthcare growth equity firm Psilos Group Managers LLC. Molecular breast imaging is an adjunct technology to mammography which radiologists use to help diagnose cancerous lesions in women with dense breast tissue. Already used in 15 prestigious medical institutions and clinical practices throughout the United States, the acquisition and investment by Psilos will enable the more focused company to meet the rapidly growing demand for LumaGEM.

The company continued its operations during the reorganization period and is moving forward with its core team of industry experts, customers and strategic business relationships intact. “Psilos’ growth capital will provide us with the funding needed to expand on our commercialization strategy,” said acting Gamma Medica CEO Jim Calandra. “Our dedicated employees have been working hard through this transition period and we’re ready to move forward to spread the use of MBI.”

“We are very impressed with the progress this team has made over the past 12-18 months in expanding LumaGEM’s customer base and making key product improvements,” said David A. Eichler, managing member at Psilos. “The growing body of clinical evidence for molecular breast imaging shows this technology’s importance in overcoming the critical shortcomings of mammography and other screening modalities in detection of cancer in dense breast tissue. We are excited about the great opportunities that lie ahead.”

Psilos, which has approximately $600 million under its management, has been an investor in Gamma Medica since 2009. Eichler and Psilos Senior Managing Member Albert S. Waxman, Ph.D., will serve on the Gamma Medica board of directors.

LumaGEM is embraced by clinicians because it clearly highlights tumors, even those obscured by dense breast tissue. LumaGEM’s 91 percent sensitivity and 93 percent specificity when used in conjunction with mammography allows physicians to detect cancer earlier, especially in the approximately 40 percent of women who have dense breasts, where fibrous tissue can obscure the view of mammography

For more information: www.gammamedica 

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
The ASPIRE Cristalle FFDM system with DBT combines Fujifilm’s state-of-the-art hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow
News | Women's Health | August 01, 2017
Fujifilm Medical Systems U.S.A., Inc. announced that The Mammography Center of Monterey, an ACR-accredited breast...
Sponsored Content | Videos | Breast Imaging | July 28, 2017
Nancy Cappello, Ph.D., executive director and founder of Are You Dense Inc. and Are You Dense Advocacy, explains how
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Kubtec Launches New Website For Digital Imaging and Irradiation Products
News | Digital Radiography (DR) | July 20, 2017
Kubtec announced the launch a new website focused on the applications of digital X-ray imaging and irradiation for...
Overlay Init